Los efectos mximos en control glucmico y peso generalmente se alcanzan entre las 20-72 semanas de tratamiento continuo
If the denial is due to insufficient documentation or failure to meet step therapy requirements, an appeal with additional clinical information may be successful
Aalberg, K., Stavem, K., Norheim, F., Russell, M
The FDA and the EMA have stated that after review of published and unpublished reports, the current data do not support an increased risk of pancreatitis and pancreatic cancer in patients receiving incretin mimetics
Its also useful for those with certain medical conditions that may lead to low levels of L-Carnitine in the body, such as heart disease or metabolic disorders